Aberrant activation of the STING signaling pathway is involved with aging-related inflammation, yet no STING-targeting therapeutics are clinically approved. Here, we identify Omaveloxolone, an FDA-approved drug for Friedreich’s ataxia, as a potent STING degrader (DC50 = 118 nM, Dmax = 98.6%) via high-throughput screening.
This study implicates Omaveloxolone as a molecular crowbar-like STING degrader and provides a mechanistic framework for targeting STING via conformational perturbation.